ELV
Elevance Health, Inc.
$418.15
+0.63%
$90.8B
No data for this timeframe.
Vol
Market Cap$90.8B
Cap SizeLarge Cap
Analyst ConsensusBuy (59%)
Inst. Holders12 funds
Inst. Value$12.2B
Inst. Activity1 buys / 1 sells
Insider Activity1B / 3S
Insider Net $-$665.8K
SEC Reports4
Congressional1 trades
Recent Activity
Jun 5, 2026
short_volume
Short Volume: ELV — 64.4% short (0.5M / 0.7M)
Short: 452,008 | Exempt: 1,535 | TRF Vol: 702,288 | Short Ratio: 64.4% | Off-exchange volume (dark p
May 19, 2026
Insider
Penczek Ronald W sold 1,531 shares
CAO & Controller @ $403.13 ($617.2K)
May 19, 2026
Insider
Penczek Ronald W sold 654 shares
CAO & Controller @ $271.27 ($177.4K)
May 19, 2026
Insider
Penczek Ronald W sold 654 shares
CAO & Controller @ $0.00 ($0.00)
Apr 22, 2026
SEC
Elevance Health reported Q1 2026 earnings of $8.00 GAAP EPS, missing consensus by 26.2% despite raising full-year adjust
8-K — Impact 7/10
Mar 27, 2026
SEC
Elevance Health is holding its 2026 annual shareholder meeting to vote on director elections, executive compensation, au
DEFA14A — Impact 3/10
Mar 23, 2026
SEC
Analysis based on filing metadata only — document content was unavailable. This is an insider trading cluster filing for
CLUSTER — Impact 3/10
Inst.
NORGES BANK — NEW
3,018,586 shares ($1.1B)
Price Targets
$415.81
-2.0% upside
Hold
Current $424.43
Low $331.00
Median $400.00
High $498.00
21 analysts
$331.00
$498.00
Analyst Ratings
6Strong Buy
11Buy
12Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Jun 8, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Jun 4, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| Jun 4, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
| Jun 1, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $6.20 | $6.06 — $6.73 | -30% YoY | 19 |
| Next Q | $5.10 | $3.90 — $6.02 | -15% YoY | 19 |
| Current FY | $26.91 | $26.72 — $28.25 | -11% YoY | 21 |
| Next FY | $29.25 | $28.64 — $31.00 | 9% YoY | 22 |
Latest Reports
BEARISH
8-K
7/10
Elevance Health reported Q1 2026 earnings of $8.00 GAAP EPS, missing consensus by 26.2% despite raising full-year adjust
Apr 22, 2026
NEUTRAL
DEFA14A
3/10
Elevance Health is holding its 2026 annual shareholder meeting to vote on director elections, executive compensation, au
Mar 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $8.1B | — |
| NORGES BANK | $1.1B | NEW |
| MORGAN STANLEY | $883.8M | — |
| BANK OF AMERICA CORP | $773.7M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $609.2M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 19, 2026 | Penczek Ronald | SELL | $617.2K |
| May 19, 2026 | Penczek Ronald | M | $177.4K |
| May 19, 2026 | Penczek Ronald | M | $0.00 |
| May 13, 2026 | COLLIS STEVEN | A | $0.00 |
| May 13, 2026 | DeVore Susan | A | $0.00 |
Congressional Trades
1 members: 1 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Markwayne Mullin | R | BUY | $15,001 - $50,000 |
12 institutional holders with $12.2B total value (34,888,484 shares) as of 2025-Q4. Top holders: VANGUARD, NORGES, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 23,019,518 | $8.1B | 66.0% | — |
| 2 | NORGES BANK | 3,018,586 | $1.1B | 8.7% | NEW |
| 3 | MORGAN STANLEY | 2,521,123 | $883.8M | 7.2% | — |
| 4 | BANK OF AMERICA CORP /DE/ | 2,207,140 | $773.7M | 6.3% | — |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,737,722 | $609.2M | 5.0% | NEW |
| 6 | FMR LLC | 1,479,271 | $518.6M | 4.2% | TRIM -29.6% |
| 7 | WELLS FARGO & COMPANY/MN | 361,845 | $126.8M | 1.0% | — |
| 8 | YACKTMAN ASSET MANAGEMENT LP | 328,756 | $115.2M | 0.9% | — |
| 9 | Mawer Investment Management Ltd. | 207,095 | $72.6M | 0.6% | ADD +34.7% |
| 10 | Tweedy, Browne Co LLC | 3,128 | $1.1M | 0.0% | NEW |
| 11 | TWO SIGMA INVESTMENTS, LP | 3,000 | $1.1M | 0.0% | NEAR_EXIT -97.4% |
| 12 | DODGE & COX | 1,300 | $455.7K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 3,018,586 | — | $1.1B | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 117,289 | 3,000 | -97.4% | $1.1M | 2025-Q4 |
| Mawer Investment Management Ltd. | ADD | 138,539 | 186,657 | +34.7% | $60.3M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 302,659 | 117,289 | -61.2% | $37.9M | 2025-Q3 |
| Tweedy, Browne Co LLC | NEW | — | 2,696 | — | $871.1K | 2025-Q3 |
| NORGES BANK | EXIT | 2,952,434 | 0 | -100.0% | $0.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 53,573 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 2,952,434 | — | $1.1B | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 27,563 | 302,659 | +998.1% | $117.7M | 2025-Q2 |
| Mawer Investment Management Ltd. | NEW | — | 138,539 | — | $53.9M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 53,573 | — | $20.8M | 2025-Q2 |
| FMR LLC | TRIM | 2,192,731 | 1,544,587 | -29.6% | $671.8M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 501,494 | 27,563 | -94.5% | $12.0M | 2025-Q1 |
| NORGES BANK | EXIT | 3,076,753 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 122,973 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | ADD | 1,005,940 | 1,343,540 | +33.6% | $495.6M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 341,990 | 644,034 | +88.3% | $237.6M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 122,973 | — | $45.4M | 2024-Q4 |
| SOUND SHORE MANAGEMENT INC /CT/ | EXIT | 119,497 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,611,242 | — | $837.8M | 2024-Q3 |
17 unique insiders with 4 transactions. Net insider value: -$665.8K ($869.5K bought, $1.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | Penczek Ronald W | CAO & Controller | SELL | 1,531 | $403.13 | $617.2K |
| May 19, 2026 | Penczek Ronald W | CAO & Controller | M | 654 | $271.27 | $177.4K |
| May 19, 2026 | Penczek Ronald W | CAO & Controller | M | 654 | $0.00 | $0.00 |
| May 13, 2026 | COLLIS STEVEN H | Director | A | 563 | $0.00 | $0.00 |
| May 13, 2026 | DeVore Susan D. | Director | A | 563 | $0.00 | $0.00 |
| May 13, 2026 | HAY LEWIS III | Director | A | 563 | $0.00 | $0.00 |
| May 13, 2026 | Dixon Robert L JR | Director | A | 563 | $0.00 | $0.00 |
| May 13, 2026 | Neri Antonio F | Director | A | 563 | $0.00 | $0.00 |
| May 13, 2026 | Schneider Ryan M. | Director | A | 563 | $0.00 | $0.00 |
| May 13, 2026 | SCHULMAN AMY W | Director | A | 563 | $0.00 | $0.00 |
| May 13, 2026 | STRABLE-SOETHOUT DEANNA D | Director | A | 563 | $0.00 | $0.00 |
| Mar 12, 2026 | SCHULMAN AMY W | Director | SELL | 26 | $287.50 | $7.5K |
| Mar 6, 2026 | Kendrick Charles Morgan JR | EVP & President, Commercial | SELL | 3,196 | $284.92 | $910.6K |
| Mar 5, 2026 | COLLIS STEVEN H | Director | BUY | 3,000 | $289.84 | $869.5K |
| Mar 3, 2026 | Wessling Erin M | EVP & Chief Legal Officer | F | 417 | $284.03 | $118.4K |
| Mar 3, 2026 | Penczek Ronald W | CAO & Controller | F | 37 | $284.03 | $10.5K |
| Mar 3, 2026 | Kendrick Charles Morgan JR | EVP & President, Commercial | F | 467 | $284.03 | $132.6K |
| Mar 3, 2026 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | F | 496 | $284.03 | $140.9K |
| Mar 3, 2026 | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | F | 446 | $284.03 | $126.7K |
| Mar 3, 2026 | Craig Ryan R | EVP & Chief HR Officer | F | 309 | $284.03 | $87.8K |
| Mar 3, 2026 | BOUDREAUX GAIL | President and CEO | F | 1,736 | $284.03 | $493.1K |
| Mar 3, 2026 | Kaye Mark | EVP & CFO | F | 353 | $284.03 | $100.3K |
| Mar 3, 2026 | LAVU RATNAKAR | EVP & Chief Digital Info Ofr | F | 222 | $284.03 | $63.1K |
| Mar 2, 2026 | Craig Ryan R | EVP & Chief HR Officer | A | 11,754 | $0.00 | $0.00 |
| Mar 2, 2026 | Penczek Ronald W | CAO & Controller | F | 131 | $294.07 | $38.5K |
| Mar 2, 2026 | Penczek Ronald W | CAO & Controller | A | 1,677 | $0.00 | $0.00 |
| Mar 2, 2026 | Kaye Mark | EVP & CFO | F | 271 | $294.07 | $79.7K |
| Mar 2, 2026 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | F | 1,421 | $294.07 | $417.9K |
| Mar 2, 2026 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | A | 23,512 | $0.00 | $0.00 |
| Mar 2, 2026 | LAVU RATNAKAR | EVP & Chief Digital Info Ofr | A | 20,152 | $0.00 | $0.00 |
| Mar 2, 2026 | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | F | 1,201 | $294.07 | $353.2K |
| Mar 2, 2026 | Wessling Erin M | EVP & Chief Legal Officer | A | 2,976 | $0.00 | $0.00 |
| Mar 2, 2026 | BOUDREAUX GAIL | President and CEO | F | 6,713 | $294.07 | $2.0M |
| Mar 2, 2026 | BOUDREAUX GAIL | President and CEO | A | 63,818 | $0.00 | $0.00 |
| Mar 2, 2026 | Wessling Erin M | EVP & Chief Legal Officer | A | 11,754 | $0.00 | $0.00 |
| Mar 2, 2026 | Craig Ryan R | EVP & Chief HR Officer | F | 25 | $294.07 | $7.4K |
| Mar 2, 2026 | Kendrick Charles Morgan JR | EVP & President, Commercial | F | 1,211 | $294.07 | $356.1K |
| Mar 2, 2026 | Kendrick Charles Morgan JR | EVP & President, Commercial | A | 15,870 | $0.00 | $0.00 |
| Mar 2, 2026 | Kaye Mark | EVP & CFO | A | 25,188 | $0.00 | $0.00 |
| Mar 2, 2026 | LAVU RATNAKAR | EVP & Chief Digital Info Ofr | F | 315 | $294.07 | $92.6K |
| Feb 2, 2026 | SCHULMAN AMY W | Director | A | 218 | $0.00 | $0.00 |
| Feb 2, 2026 | Craig Ryan R | EVP & Chief HR Officer | F | 279 | $341.83 | $95.4K |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.3/10.
BEARISH
8-K
7/10
Elevance Health reported Q1 2026 earnings of $8.00 GAAP EPS, missing consensus by 26.2% despite rais
Apr 22, 2026
NEUTRAL
DEFA14A
3/10
Elevance Health is holding its 2026 annual shareholder meeting to vote on director elections, execut
Mar 27, 2026
NEUTRAL
CLUSTER
3/10
Analysis based on filing metadata only — document content was unavailable. This is an insider tradin
Mar 23, 2026
NEUTRAL
CLUSTER
4/10
An insider trading cluster at Elevance Health shows one open-market purchase and one sale by executi
Mar 9, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (59% buy). Based on 29 analysts: 6 strong buy, 11 buy, 12 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$415.81 mean target
-2.0% upside
Hold (1.82)
$331.00 Low
$498.00 High
| Metric | Value |
|---|---|
| Current Price | $424.43 |
| Target Low | $331.00 |
| Target Mean | $415.81 |
| Target Median | $400.00 |
| Target High | $498.00 |
| # Analysts | 21 |
| Recommendation | Hold (1.82) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$6.20 | $6.06 | $6.73 | -29.8% | +0.0% | 9↑ 9↓ | $48.6B | -1.6% | 19 |
| Next Q 2026-09-30 |
$5.10 | $3.90 | $6.02 | -15.5% | +0.0% | 3↑ 15↓ | $48.6B | -2.9% | 19 |
| Current FY 2026-12-31 |
$26.91 | $26.72 | $28.25 | -11.2% | -0.0% | 20↑ 1↓ | $194.2B | -1.7% | 21 |
| Next FY 2027-12-31 |
$29.25 | $28.64 | $31.00 | 8.7% | +0.1% | 16↑ 2↓ | $198.5B | 2.2% | 22 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $6.205 | |
| 7d ago | $6.205 | |
| 30d ago | $6.205 | |
| 60d ago | $6.542 | -0.337 |
| 90d ago | $6.615 | -0.411 |
14 analyst firms have rated this stock: 3 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Jun 8, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jun 4, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Jun 4, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Jun 1, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 26, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 22, 2026 | UBS | MAINTAIN | Buy | Buy |
| May 20, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 20, 2026 | Deutsche Bank | UPGRADE | Hold | Buy |
| Apr 29, 2026 | B of A Securities | UPGRADE | Neutral | Buy |
| Apr 28, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Apr 24, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 24, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Apr 23, 2026 | Evercore ISI Group | MAINTAIN | In-Line | In-Line |
| Apr 23, 2026 | Baird | MAINTAIN | Neutral | Neutral |
| Apr 20, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Apr 13, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | Evercore ISI Group | INITIATE | — | In-Line |
| Mar 11, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 2, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 2, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 30, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 30, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 29, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 22, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Jan 7, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 5, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Dec 19, 2025 | Deutsche Bank | DOWNGRADE | Buy | Hold |
| Dec 18, 2025 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 11 | 12 | 0 | 0 | 59% | |
| May 1, 2026 | 6 | 10 | 13 | 0 | 0 | 55% | |
| Apr 1, 2026 | 5 | 10 | 13 | 0 | 0 | 54% | |
| Mar 1, 2026 | 5 | 10 | 13 | 0 | 0 | 54% | |
| Feb 1, 2026 | 5 | 11 | 12 | 0 | 0 | 57% | |
| Jan 1, 2026 | 4 | 11 | 13 | 0 | 0 | 54% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 1 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Dec 29, 2025 | Markwayne Mullin | R | SENATE | BUY | $15,001 - $50,000 | Elevance Health Inc | Jan 16, 2026 (19d) |
Recent Reddit Threads
Jun 5, 2026
short_volume
Short Volume: ELV — 64.4% short (0.5M / 0.7M)
Short: 452,008 | Exempt: 1,535 | TRF Vol: 702,288 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: ELV — 72.5% short (0.5M / 0.6M)
Short: 455,899 | Exempt: 498 | TRF Vol: 628,445 | Short Ratio: 72.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: ELV — 2.0M shares, 65,286 trades
Week starting 2026-05-18. Total ATS volume: 1,954,039 shares across 65,286 trades.
May 13, 2026
short_volume
Short Volume: ELV — 57.7% short (0.6M / 1.0M)
Short: 592,403 | Exempt: 2,384 | TRF Vol: 1,026,306 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: ELV — 3.5M shares, 83,102 trades
Week starting 2026-05-11. Total ATS volume: 3,467,791 shares across 83,102 trades.
May 4, 2026
dark_pool
Dark Pool: ELV — 1.8M shares, 56,443 trades
Week starting 2026-05-04. Total ATS volume: 1,762,777 shares across 56,443 trades.
Apr 28, 2026
short_volume
Short Volume: ELV — 56.8% short (0.4M / 0.6M)
Short: 364,659 | Exempt: 2,209 | TRF Vol: 642,159 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
dark_pool
Dark Pool: ELV — 3.0M shares, 84,276 trades
Week starting 2026-04-27. Total ATS volume: 2,995,246 shares across 84,276 trades.
Apr 22, 2026
earnings_calendar
ELV Q1 2026 Earnings Before Market Open — 2026-04-22
Apr 20, 2026
dark_pool
Dark Pool: ELV — 3.7M shares, 98,476 trades
Week starting 2026-04-20. Total ATS volume: 3,695,985 shares across 98,476 trades.
Apr 14, 2026
short_volume
Short Volume: ELV — 69.1% short (0.6M / 0.8M)
Short: 568,427 | Exempt: 0 | TRF Vol: 822,578 | Short Ratio: 69.1% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
dark_pool
Dark Pool: ELV — 1.9M shares, 63,765 trades
Week starting 2026-04-13. Total ATS volume: 1,874,024 shares across 63,765 trades.
Apr 7, 2026
short_volume
Short Volume: ELV — 60.1% short (0.5M / 0.8M)
Short: 487,131 | Exempt: 396 | TRF Vol: 810,458 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
dark_pool
Dark Pool: ELV — 1.8M shares, 64,642 trades
Week starting 2026-04-06. Total ATS volume: 1,804,495 shares across 64,642 trades.
Apr 2, 2026
short_volume
Short Volume: ELV — 60.3% short (0.3M / 0.5M)
Short: 309,598 | Exempt: 159 | TRF Vol: 513,307 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)